#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Germ cell cancer Acute graft versus host disease in liver Soft tissue sarcoma Juvenile idiopathic arthritis Acute graft versus host disease Fibrodysplasia ossificans progressiva Nephropathy Gastrointestinal neuroendocrine tumour Squamous cell carcinoma of head and neck Progressive familial intrahepatic cholestasis Meningitis meningococcal Hypersomnia Diabetes insipidus Follicular lymphoma stage I Skin angiosarcoma More trials…

    Learn about Rare Diseases

    Angiosarcoma metastatic – Diagnostics Hereditary angioedema with C1 esterase inhibitor deficiency – Basic Information Gaucher’s disease type III – Basic Information Pemphigus – Basic Information Langerhans’ cell histiocytosis – Life with Disease Rhabdoid tumour Haemophilia A with anti factor VIII – Life with Disease Haemophilia – Life with Disease Behcet’s syndrome Waldenstrom’s macroglobulinaemia refractory – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Indocyanine Green Amg 193 Garetosmab Iohexol Mosunetuzumab Highly Refined Fish Oil Midostaurin Amcenestrant Vo659 Atacicept Alpha-Tocopherol Sym023 Ilofotase Alfa Brexpiprazole ATIGOTATUG Desvenlafaxine Benzoate Ofloxacin Quetiapine Safinamide Juniper Berry Oil More therapies…

    Learn about Your Condition

    Macular oedema Endometrial cancer stage I Tympanic membrane hyperaemia Neuralgia Genital herpes Heart transplant Radiation skin injury Venous thrombosis Atrophic vulvovaginitis Eye pain Staphylococcal infection Autoimmune disorder Turner's syndrome Metastases to biliary tract Varicella More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Relapsing-remitting multiple sclerosis

  • Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Relapsing-remitting multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    Belgium Bulgaria Croatia Czechia Denmark France +9

  • Study on the Effectiveness of Autologous Stem Cell Transplantation with Cytarabine in Patients with Aggressive Multiple Sclerosis

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Alemtuzumab
    • Anti-Human T-Lymphocyte Immunoglobulin From Rabbits
    • Melphalan Flufenamide
    Italy

  • Study Comparing Rituximab and Ocrelizumab for Patients with Active Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Secondary progressive multiple sclerosis
    • Primary progressive multiple sclerosis
    • Relapsing-remitting multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    • Rituximab
    Denmark

  • Study on the Safety and Efficacy of CLS12311 and Autologous Red Blood Cells for Patients with Relapsing Remitting Multiple Sclerosis

    Not recruiting

    1 1
    Investigated Diseases:
    • Relapsing-remitting multiple sclerosis
    Investigated Drugs:
    • Cls12311
    Czechia Germany Italy

  • Study on the Effects of Obexelimab for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    2 1
    Investigated Drugs:
    • Obexelimab
    Austria Belgium Croatia Czechia Denmark Finland +4

  • Study on Testosterone Undecanoate for Neuroprotection and Myelin Repair in Patients with Relapsing Remitting Multiple Sclerosis

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Testosterone Undecanoate
    France
Previous Page
1 2 3 4
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!